The tumors treated with 131I-hu4G4 possessed more activated CD8+ cytotoxic T lymphocytes among the tumor-infiltrating lymphocytes (26.69 ± 3.01 %) than those treated with PBS (7.75 ± 1.42 %), hu4G4 (8.90 ± 0.84 %), or Na131I (12.58 ± 2.74 %), as shown in Figure 4A, 4B. The gene discussed is CD8A; the disease is neoplasm.